Infectious Diseases and Therapy (Oct 2023)

Rapid Response to Remdesivir in Hospitalised COVID-19 Patients: A Propensity Score Weighted Multicentre Cohort Study

  • Emiel Leegwater,
  • Lisa Dol,
  • Menno R. Benard,
  • Eveline E. Roelofsen,
  • Nathalie M. Delfos,
  • Machteld van der Feltz,
  • Femke P. N. Mollema,
  • Liesbeth B. E. Bosma,
  • Loes E. Visser,
  • Thomas H. Ottens,
  • Nathalie D. van Burgel,
  • Sesmu M. Arbous,
  • Lahssan H. El Bouazzaoui,
  • Rachel Knevel,
  • Rolf H. H. Groenwold,
  • Mark G. J. de Boer,
  • Leo G. Visser,
  • Frits R. Rosendaal,
  • Erik B. Wilms,
  • Cees van Nieuwkoop

DOI
https://doi.org/10.1007/s40121-023-00874-2
Journal volume & issue
Vol. 12, no. 10
pp. 2471 – 2484

Abstract

Read online

Abstract Introduction Remdesivir is a registered treatment for hospitalised patients with COVID-19 that has moderate clinical effectiveness. Anecdotally, some patients’ respiratory insufficiency seemed to recover particularly rapidly after initiation of remdesivir. In this study, we investigated if this rapid improvement was caused by remdesivir, and which patient characteristics might predict a rapid clinical improvement in response to remdesivir. Methods This was a multicentre observational cohort study of hospitalised patients with COVID-19 who required supplemental oxygen and were treated with dexamethasone. Rapid clinical improvement in response to treatment was defined by a reduction of at least 1 L of supplemental oxygen per minute or discharge from the hospital within 72 h after admission. Inverse probability of treatment-weighted logistic regression modelling was used to assess the association between remdesivir and rapid clinical improvement. Secondary endpoints included in-hospital mortality, ICU admission rate and hospitalisation duration. Results Of 871 patients included, 445 were treated with remdesivir. There was no influence of remdesivir on the occurrence of rapid clinical improvement (62% vs 61% OR 1.05, 95% CI 0.79–1.40; p = 0.76). The in-hospital mortality was lower (14.7% vs 19.8% OR 0.70, 95% CI 0.48–1.02; p = 0.06) for the remdesivir-treated patients. Rapid clinical improvement occurred more often in patients with low C-reactive protein (≤ 75 mg/L) and short duration of symptoms prior to hospitalisation (< 7 days) (OR 2.84, 95% CI 1.07–7.56). Conclusion Remdesivir generally does not increase the incidence of rapid clinical improvement in hospitalised patients with COVID-19, but it might have an effect in patients with short duration of symptoms and limited signs of systemic inflammation.

Keywords